Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24; Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines; NDAA for Fiscal Year 2024 - provisions related to biological and chemical defense and access to naloxone.
Duration: March 1, 2014
to
present
General Issues: Disaster Planning/Emergencies , Homeland Security , Budget/Appropriations , Defense
Spending: about $1,390,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: U.S. Senate, House of Representatives, Homeland Security - Dept of (DHS), Homeland Security - Dept of (DHS), Defense - Dept of (DOD), Transportation Security Administration (TSA)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2023
In Q4, Ervin Graves Strategy Group, LLC lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Jan. 21.
Original Filing: 301534110.xml
Lobbying Issues
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24; Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines; NDAA for Fiscal Year 2024 - provisions related to biological and chemical defense and access to naloxone.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2023
In Q3, Ervin Graves Strategy Group, LLC lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Oct. 19, 2023.
Original Filing: 301507678.xml
Lobbying Issues
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act;
Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24;
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines;
State opioid response (SOR) Grant funding for FY24;
Substance Abuse and Mental Health Block Grant (SABG) funding for FY24;
NDAA for Fiscal Year 2024 - provisions related to biological and chemical defense and access to naloxone;
FAA reauthorization - increasing access to naloxone;
HANDS Act - H.R. 5506
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2023
In Q2, Ervin Graves Strategy Group, LLC lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on July 19, 2023.
Original Filing: 301482276.xml
Lobbying Issues
"Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act
Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield
State opioid response (SOR) Grant funding
NDAA for Fiscal Year 2024 - provisions related to biological and chemical defense and access to naloxone
"
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2023
In Q1, Ervin Graves Strategy Group, LLC lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on April 19, 2023.
Original Filing: 301457507.xml
Lobbying Issues
"Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act
Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield
State opioid response (SOR) Grant funding
NDAA for Fiscal Year 2024 - provisions related to biological and chemical defense and access to naloxone
"
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2022
In Q4, Ervin Graves Strategy Group, LLC lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Jan. 18, 2023.
Original Filing: 301430776.xml
Lobbying Issues
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone;
HR 2617 - Consolidated Appropriations Act, 2023 (Omnibus);
HR 1437 - Further Continuing Appropriations and Extensions Act;
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines;
Issues related to the development, manufacture, and distribution of coronavirus vaccines
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2022
In Q3, Ervin Graves Strategy Group, LLC lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Oct. 19, 2022.
Original Filing: 301408616.xml
Lobbying Issues
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
S. 3799 - PREVENT Pandemics Act
Issues related to the development, manufacture, and distribution of coronavirus vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2022
In Q2, Ervin Graves Strategy Group, LLC lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on July 20, 2022.
Original Filing: 301391015.xml
Lobbying Issues
NDAA for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone
House and Senate appropriations for FY 2023
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021
H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R 2366; S.1457 - Stop Fentanyl Act
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021
HR 7681 - Preventing Overdoses and Saving Lives Act 2.0
S. 3799 - PREVENT Pandemics Act
Issues related to the development, manufacture, and distribution of coronavirus vaccines.
HR 3263 Outreach - DHS Medical Countermeasures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2022
In Q1, Ervin Graves Strategy Group, LLC lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on April 19, 2022.
Original Filing: 301363721.xml
Lobbying Issues
H.R. 2471 - Consolidated Appropriations Act, 2022
Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021
H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R 2366; S.1457 - Stop Fentanyl Act
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021
Issues related to the development, manufacture, and distribution of coronavirus vaccines
HR 3263 Outreach - DHS Medical Countermeasures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2021
In Q4, Ervin Graves Strategy Group, LLC (f/k/a Ervin Hill Strategy) lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Jan. 20, 2022.
Original Filing: 301334294.xml
Lobbying Issues
Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act;
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone;
State Opioid Response (SOR) Grants funding;
H.R. 2379 - The State Opioid Response Grant Authorization Act of 2021;
Substance Abuse and Mental Health Block Grant (SABG) funding;
H.R. 4341; S. 987 - CARA 3.0 - Comprehensive Addiction and Recovery Act
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R 2366; S.1457 - Stop Fentanyl Act;
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021;
Issues related to the development, manufacture, and distribution of coronavirus vaccines;
HR 3263 Outreach - DHS Medical Countermeasures Act;
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2021
In Q3, Ervin Graves Strategy Group, LLC (f/k/a Ervin Hill Strategy) lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301307199.xml
Lobbying Issues
State Opioid Response Grants funding;
Substance Abuse and Mental Health Block Grant funding;
CARA 3.0 - Comprehensive Addiction and Recovery Act;
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines;
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021;
Appropriations funding for Fiscal Year 2022;
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone;
S.4231 - Preparing for the Next Pandemic Act;
H.R 2366 S.1457 - Stop Fentanyl Act;
H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021;
Issues related to the development, manufacture, and distribution of coronavirus vaccines;
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
2nd Quarter, 2021
In Q2, Ervin Graves Strategy Group, LLC (f/k/a Ervin Hill Strategy) lobbied for Emergent BioSolutions Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301289748.xml
Lobbying Issues
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder;
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines;
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021;
Appropriations funding for Fiscal Year 2022;
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
1st Quarter, 2021
In Q1, Ervin Graves Strategy Group, LLC (f/k/a Ervin Hill Strategy) lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 20, 2021.
Original Filing: 301259786.xml
Lobbying Issues
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder;
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines;
H.R. 2379 The State Opioid Response Grant Authorization Act of 2021;
Appropriations funding for Fiscal Year 2022;
NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
4th Quarter, 2020
In Q4, Ervin Graves Strategy Group, LLC (f/k/a Ervin Hill Strategy) lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Jan. 20, 2021.
Original Filing: 301239291.xml
Lobbying Issues
State Opioid Response Grants funding for FY 2021;
H.R. 6395, NDAA for Fiscal Year 2021- provisions related to biological and chemical defense and access to naloxone;
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines;
H.R. 7783, "Plasma Donation Awareness Act of 2020" co-sponsored by Rep. Scott Peters and Rep. Brad Wenstrup, and S. 4179, "Plasma Donation Awareness Act" co-sponsored by Sen. Amy Klobuchar and Sen. Roger Wicker that would simply add plasma to a blood donation awareness campaign;
H.R. 2466 The State Opioid Response Grant Authorization Act;
H.R. 7574-Strengthening Americas Strategic National Stockpile Act of 2020, as amended (Rep. Slotkin - Energy and Commerce);
HEROES Act - H.R. 8406 - The Heroes Act;
S.4231 - Preparing for the Next Pandemic Act;
HEALS Act;
H.R. 14, the Commitment to Defeat the Virus and Keep America Healthy Act;
H.R. 133, Consolidated Appropriations Act 2021;
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Type of Issue
Disaster Planning/Emergencies
3rd Quarter, 2020
In Q3, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 19, 2020.
Original Filing: 301214201.xml
Lobbying Issues
Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
State Opioid Response Grants funding for FY 2021
NDAA - provisions related to biological and chemical defense
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R. 7783, "Plasma Donation Awareness Act of 2020" co-sponsored by Rep. Scott Peters and Rep. Brad Wenstrup, and S. 4179, "Plasma Donation Awareness Act" co-sponsored by Sen. Amy Klobuchar and Sen. Roger Wicker that would simply add plasma to a blood donation awareness campaign.
H.R. 2466 The State Opioid Response Grant Authorization Act
H.R. 7574-Strengthening Americas Strategic National Stockpile Act of 2020, as amended (Rep. Slotkin - Energy and Commerce)
HEROES Act - H.R.8406 - The Heroes Act
S.4231 - Preparing for the Next Pandemic Act
HEALS Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
State Opioid Response Grants funding for FY 2021
NDAA - provisions related to biological and chemical defense
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
H.R. 7783, "Plasma Donation Awareness Act of 2020" co-sponsored by Rep. Scott Peters and Rep. Brad Wenstrup, and S. 4179, "Plasma Donation Awareness Act" co-sponsored by Sen. Amy Klobuchar and Sen. Roger Wicker that would simply add plasma to a blood donation awareness campaign.
H.R. 2466 The State Opioid Response Grant Authorization Act
H.R. 7574-Strengthening Americas Strategic National Stockpile Act of 2020, as amended (Rep. Slotkin - Energy and Commerce)
HEROES Act - H.R.8406 - The Heroes Act
S.4231 - Preparing for the Next Pandemic Act
HEALS Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
2nd Quarter, 2020
In Q2, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 20, 2020.
Original Filing: 301196661.xml
Lobbying Issues
Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
State Opioid Response Grants funding for FY 2021
NDAA - provisions related to biological and chemical defense
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
State Opioid Response Grants funding for FY 2021
NDAA - provisions related to biological and chemical defense
Emergency Support for Substance Use Disorders Act/ Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder
Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
1st Quarter, 2020
In Q1, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 20, 2020.
Original Filing: 301174848.xml
Lobbying Issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, S.3548 - CARES Act, FY 2021 Appropriations
provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
NDAA - provisions related to biological and chemical defense
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, naloxone access, co- prescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020, S.3548 - CARES Act, FY 2021 Appropriations
provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
NDAA - provisions related to biological and chemical defense
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, naloxone access, co- prescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
4th Quarter, 2019
In Q4, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Jan. 21, 2020.
Original Filing: 301127299.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
3rd Quarter, 2019
In Q3, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 21, 2019.
Original Filing: 301076401.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
2nd Quarter, 2019
In Q2, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 19, 2019.
Original Filing: 301051462.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
1st Quarter, 2019
In Q1, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 22, 2019.
Original Filing: 301034355.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
4th Quarter, 2018
In Q4, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Jan. 18, 2019.
Original Filing: 301009401.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Department of Defense appropriations for Medical Countermeasures
H.R. 6378, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
FDA regulatory issues
Issues related to Priority Review Voucher programs
Opioid and heroin addiction legislation, Naloxone access, coprescribing/opioid prescribing guidelines
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
3rd Quarter, 2018
In Q3, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 19, 2018.
Original Filing: 300991735.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
2nd Quarter, 2018
In Q2, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 19, 2018.
Original Filing: 300971097.xml
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
1st Quarter, 2018
In Q1, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 18, 2018.
Original Filing: 300947182.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
4th Quarter, 2017
Ervin Hill Strategy amended a lobbying report for representation of Emergent BioSolutions Inc. in Q42017 on Jan. 24, 2018.
Original Filing: 300938254.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
4th Quarter, 2017
In Q4, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929762.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
3rd Quarter, 2017
In Q3, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 19, 2017.
Original Filing: 300909340.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government.
Re-authorization of the Pandemic and All-Hazards Preparedness Act
NDAA - provisions related to biological and chemical defense
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
2nd Quarter, 2017
In Q2, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300889598.xml
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition and stockpiling medical countermeasures
Provisions related to development, acquisition and stockpiling medical countermeasures
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2018 Appropriations - provisions related to development, acquisition and stockpiling medical countermeasures
Provisions related to development, acquisition and stockpiling medical countermeasures
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
1st Quarter, 2017
In Q1, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 20, 2017.
Original Filing: 300872583.xml
Lobbying Issues
FY17 and FY18 Appropriations- provisions related to development, acquisition, and stockpiling of medical countermeasures
Provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
Lobbying Issues
FY 2017 and FY 2018 Appropriations - provisions related to development, acquisition and stockpiling of medical countermeasures
Provisions related to development, acquisition and stockpiling of medical countermeasures for the US Government
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Disaster Planning/Emergencies Budget/Appropriations
4th Quarter, 2016
In Q4, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $20,000. The report was filed on Jan. 19, 2017.
Original Filing: 300851573.xml
Lobbying Issues
H.R. 4909 FY17 National Defense Authorization Act
H.R. 5293 Department of Defense Appropriations Act
S. 3000 Defense Appropriations Bill
S. 2943, National Defense Authorization Act
H.R. 3299 Strengthening Public Health Emergency Response Act of 2015
H.R. 1300, First Responder Anthrax Preparedness Act
S. 1915 First Responder Anthrax Preparedness Act
H.R. 5325 Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Communicated to staff regarding S. 1915 First Responder Anthrax Act Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
3rd Quarter, 2016
In Q3, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 17, 2016.
Original Filing: 300828992.xml
Lobbying Issues
H.R. 4909 FY17 National Defense Authorization Act
H.R. 5293 Department of Defense Appropriations Act
S. 3000 Defense Appropriations Bill
S. 2943, National Defense Authorization Act
H.R. 3299 Strengthening Public Health Emergency Response Act of 2015
H.R. 1300, First Responder Anthrax Preparedness Act
S. 1915 First Responder Anthrax Preparedness Act
H.R. 5325 Continuing Appropriations and Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2017, and Zika Response and Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Communicated to staff regarding S. 1915 First Responder Anthrax Act Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
2nd Quarter, 2016
In Q2, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 20, 2016.
Original Filing: 300817014.xml
Lobbying Issues
H.R. 4909 FY17 National Defense Authorization Act
H.R. 5293 Department of Defense Appropriations Act
S. 3000 Defense Appropriations Bill
S. 2943, National Defense Authorization Act
H.R. 3299 Strengthening Public Health Emergency Response Act of 2015
H.R. 1300, First Responder Anthrax Preparedness Act
S. 1915 First Responder Anthrax Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Communicated to staff regarding S. 1915 First Responder Anthrax Act Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
1st Quarter, 2016
In Q1, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 19, 2016.
Original Filing: 300795981.xml
Lobbying Issues
FY17 House and Senate Defense Appropriations Bill
FY 17 Senate NDAA Bill
H.R. 4909, FY17 National Defense Authorization Act
H.R. 329 Strengthening Public Health Emergency Response Act of 2015
H.R. 1300, First Responder Anthrax Preparedness Act
S. 1915 First Responder Anthrax Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Communicated to staff regarding S. 1915 First Responder Anthrax Act Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
4th Quarter, 2015
In Q4, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Jan. 12, 2016.
Original Filing: 300770856.xml
Lobbying Issues
H.R. 1735 National Defense Authorization Act FY16
Pending final authorization of Senate FY16 NDAA bill
Pending appropriation of FY16 defense appropriation
H.R. 1300, First Responder Anthrax Preparedness Act
S. 1915 First Responder Anthrax Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Pending final authorization of S. 1619, Department of Homeland Security Appropriations Act, 2016
Communicated to staff regarding S. 1915 First Responder Anthrax Act Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
3rd Quarter, 2015
In Q3, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763530.xml
Lobbying Issues
H.R. 1735 National Defense Authorization Act FY16
Pending final authorization of Senate FY16 NDAA bill
Pending appropriation of FY16 defense appropriation
H.R. 1300, First Responder Anthrax Preparedness Act
S. 1915 First Responder Anthrax Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Pending final authorization of S. 1619, Department of Homeland Security Appropriations Act, 2016
Communicated to staff regarding S. 1915 First Responder Anthrax Act Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
2nd Quarter, 2015
In Q2, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 20, 2015.
Original Filing: 300744599.xml
Lobbying Issues
Pending final authorization of House and Senate FY16 NDAA bill
Pending appropriation of FY16 defense appropriation
H.R. 1300, First Responder Anthrax Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Pending final authorization of S. 1619, Department of Homeland Security Appropriations Act, 2016
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
1st Quarter, 2015
In Q1, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on April 20, 2015.
Original Filing: 300725609.xml
Lobbying Issues
Pending final authorization of House and Senate FY16 NDAA bill
H.R. 1300, First Responder Anthrax Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Pending final authorization of House and Senate FY16 NDAA bill
H.R. 1300, First Responder Anthrax Preparedness Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS) Transportation Security Administration (TSA)
4th Quarter, 2014
In Q4, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Jan. 20, 2015.
Original Filing: 300705325.xml
Lobbying Issues
Pending final passage of H.R. 4435, Howard P. "Buck" McKeon National Defense Authorization Act for Fiscal Year 2015; Chem Bio, RSDL
Pending final passage of S. 2410, Carl Levin National Defense Authorization Act for Fiscal Year 2015; Chem Bio, RSDL
Pending final passage of H.R. 2397, Department of Defense Appropriation Act, 2014; Chem Bio, RSDL
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Authorization of H.R. 3846, United States Customs and Border Protection Authorization Act, RSDL, First Responder Protection
Appropriation of H.R. 2903, Department of Homeland Security Appropriations Act, RSDL, First Responder Protection
Appropriation of S. 1284, Department of Labor, Health and Human Services and Education and related Agencies Appropriations Act; SRF, First Responder Protection, CFAX, Strategic Stockpile
Appropriation of H.R. 4903, Department of Homeland Security Appropriation Act; SRF, First Responder Protection, CFAX, Strategic Stockpile
Outreach to key members in Congress to co-sponsor legislation regarding First Responder Protection
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS) Transportation Security Administration (TSA)
3rd Quarter, 2014
In Q3, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on Oct. 20, 2014.
Original Filing: 300684366.xml
Lobbying Issues
Pending final passage of H.R. 4435, Howard P. "Buck" McKeon National Defense Authorization Act for Fiscal Year 2015; Chem Bio, RSDL
Pending final passage of S. 2410 Carl Levin National Defense Authorization Act for Fiscal Year 2015; Chem Bio, RSDL
Pending final passage of H.R. 2397, Department of Defense Appropriation Act, 2014; Chem Bio, RSDL
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Authorization of H.R. 3846, United States Customs and Border Protection Authorization Act, RSDL, First Responders Protection
Appropriation of H.R. 2903, Department of Homeland Security Appropriations Act, RSDL, First Responder Protection
Appropriation of S. 1284, Departments of Labor, Health and Human Services, and Education, and related Agencies Appropriations Act; SRF, First Responders Protection, CFAX, Strategic Stockpile
Appropriation of H.R. 4903, Department of Homeland Security Appropriation Act; SRF, First Responders Protection, CFAX, Strategic Stockpile
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
2nd Quarter, 2014
In Q2, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $30,000. The report was filed on July 21, 2014.
Original Filing: 300667294.xml
Lobbying Issues
Pending final passage of H.R. 4435, Howard P. "Buck" McKeon National Defense Authorization Act for Fiscal Year 2015; Chem Bio, RSDL
Pending final passage of S. 2410, Carl Levin National Defense Authorization Act for Fiscal Year 2015; Chem Bio, RSDL
Pending final passage of H.R. 2397, Department of Defense Appropriations Act, 2014; Chem Bio, RSDL
Agencies Lobbied
U.S. Senate U.S. House of Representatives Defense - Dept of (DOD)
Lobbying Issues
Authorization of H.R. 3846, United States Customs and Border Protection Authorization Act; RSDL, First Responder Protection
Appropriation of H.R. 4903, Department of Homeland Security Appropriations Act; RSDL, First Responder Protection
Appropriation of S. 1284, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; SRF, First Responder Protection, CFAX, Strategic Stockpile
Appropriation of H.R. 4903, Department of Homeland Security Appropriations Act; SRF, First Responder Protection, CFAX, Strategic Stockpile
Agencies Lobbied
U.S. Senate U.S. House of Representatives Homeland Security - Dept of (DHS)
1st Quarter, 2014
In Q1, Ervin Hill Strategy lobbied for Emergent BioSolutions Inc. , earning $10,000. The report was filed on April 17, 2014.
Original Filing: 300640084.xml
Lobbying Issues
Preparation for lobbying; chemical and biological vaccines and antidotes
Agencies Lobbied
Homeland Security - Dept of (DHS)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate